Local Pump Thrombus Lysis: First In vitro Results with the VAD Maintenance System

Feldmann, C.; Deniz, E.; Stomps, A.; Hanke, Jasmin S.; Rojas, Sebastián V.; Dogan, Guenes; Haverich, Axel; Schmitto, Jan D.

doi:10.1055/s-0037-1598793

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is however, potential for further miniaturization of the pump, as well as optimization of blood flow and pressure measurements. There is already research ongoing to this end, as well as for prevention of post-operative complications such as early and effective thrombus detection and treatment after HVAD implantation, especially through acoustic spectral analysis (31). Efforts are ongoing for optimization of pump speed control and modulation, by redesigning the underlying software, electronics and controller units.…”

Section: Future Directionsmentioning

confidence: 99%

Clinical overview of the HVAD: a centrifugal continuous-flow ventricular assist device with magnetic and hydrodynamic bearings including lateral implantation strategies

Chatterjee¹,

Feldmann²,

Dogan³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Growing worldwide incidences of end-stage heart failure and declining rates of cardiac transplants have given rise to the need for alternative treatment options, based on mechanical circulatory support (MCS) devices such as left ventricular assist devices (LVADs). Technologically advanced LVADs such as the HVAD (HeartWare, Medtronic) facilitate safe and efficient treatment of heart failure patients with reduced post-operative complications, which is attributed to their considerably miniaturized size. This also facilitates the development and implementation of novel, minimally-invasive surgical techniques. The HVAD is a centrifugal pump, manufactured by HeartWare Inc., (Framingham, MA, USA) and subsequently by Medtronic Inc., (Minnesota, MN, USA), and has been approved for clinical application after receiving the CE Mark approval in 2008 and the FDA approval in 2012. Current research efforts are focused on further miniaturization alongside optimization of electronic and software controllers as well as implementation of the transcutaneous energy transfer (TET) technology. Salient features of the HVAD pump technology, clinical applications and future optimization strategies have been discussed in this article.

show abstract

Section: Future Directionsmentioning

confidence: 99%